Arcxis Gets Investment from In-Q-Tel | GenomeWeb

NEW YORK (GenomeWeb News) – Arcxis Biotechnologies said today that it has inked a partnership with In-Q-Tel to accelerate development and commercialization of the firm's nucleic acid sample preparation platform and diagnostic consumable product line.

Arcxis said the investment from In-Q-Tel is linked to the firm's recent round of private financing led by Claremont Creek Ventures, Kaiser Permanente Ventures, and Alafi Capital. The firm has not disclosed how much money it raised in that series B round, and it is not disclosing the amount of funding it has received from In-Q-Tel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.